Mycophenolate Mofetil: Best SSc Immunosuppression
- Mycophenolate mofetil offers "robust" benefits as a primary treatment for diffuse cutaneous systemic sclerosis, according to research in ACR Open rheumatology.
- Spiera, director of the scleroderma, vasculitis and myositis center at Hospital for Special Surgery, noted the limited options for treating scleroderma.
- Spiera and his team analyzed data from the RESOLVE-1 trial, which investigated lenabasum for diffuse cutaneous SSc.
Discover how mycophenolate mofetil, a promising immunosuppressant, is reshaping treatment for systemic sclerosis. News Directory 3 reports that this study reveals superior outcomes in skin and lung health, especially with early intervention. Specifically, mycophenolate mofetil demonstrated considerable benefits over methotrexate and steroids in cases of diffuse cutaneous systemic sclerosis, perhaps changing treatment paradigms.The study highlights the importance of timely treatment, offering hope for patients. What are the broader implications of this shift, and how can it affect those living with SSc? Discover what’s next.
Mycophenolate mofetil shows Promise in Treating Systemic Sclerosis
Updated June 4, 2025
Mycophenolate mofetil offers “robust” benefits as a primary treatment for diffuse cutaneous systemic sclerosis,
according to research in ACR Open rheumatology. The study indicated that mycophenolate mofetil (MMF)
outperforms methotrexate, steroids, and other immunosuppressants, especially when started early or for
interstitial lung disease.
Dr. Robert F. Spiera, director of the scleroderma, vasculitis and myositis center at Hospital for Special
Surgery, noted the limited options for treating scleroderma. “We have some drugs which have been shown to be
helpful for specific disease manifestations, most notably interstitial lung disease, but there hasn’t been a
recognized global disease-modifying drug recognized as being effective in systemic sclerosis,” Spiera told
healio.
Spiera and his team analyzed data from the RESOLVE-1 trial, which investigated lenabasum for diffuse cutaneous
SSc. Although lenabasum itself showed no important benefit, the trial’s design allowed researchers to compare
the effectiveness of different background immunosuppressive therapies used at the discretion of the
investigators.
The analysis compared outcomes among patients receiving:
- No immunosuppressive therapy
- mycophenolate mofetil, with or without other immunosuppressants
- Methotrexate, with or without other immunosuppressants (excluding mycophenolate mofetil)
- Steroids, with or without other immunosuppressants (excluding mycophenolate mofetil)
- Other immunosuppressants, such as azathioprine, hydroxychloroquine, or rituximab
The study found that mycophenolate mofetil had the most significant impact on skin disease, especially in
patients treated within two years of diagnosis. These patients showed a mean –10.8-point change in modified
Rodnan skin score at week 52, compared to a –4.8-point change in those receiving no immunosuppression.
Similarly, early treatment with mycophenolate mofetil stabilized lung function, while those without
immunosuppression experienced greater losses in forced vital capacity. The forced vital capacity changes in other
treatment groups landed between those of patients who received mycophenolate mofetil and no immunosuppressive
therapy.
Spiera emphasized the importance of early intervention for lung outcomes, noting the significant benefits seen
with mycophenolate mofetil in patients with anti-topoisomerase 1 autoantibodies.
“Treatment with mycophenolate was associated with better outcomes than treatment with any other regimen that did
not include mycophenolate,” Spiera said. “It was the first time that this has been shown, I think, in such a
robust way.”
Spiera believes this analysis offers compelling evidence that could shift the treatment approach for systemic
sclerosis, thanks to its use of high-quality trial data.
What’s next
the findings may lead to broader adoption of mycophenolate mofetil as a first-line treatment for diffuse
cutaneous systemic sclerosis, particularly in early-stage disease.